학술논문
Loss of the epithelial marker CDX1 predicts poor prognosis in early-stage CRC patients.
Document Type
Academic Journal
Author
Solé L; Program in Cancer Research, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.; Lobo-Jarne T; Program in Cancer Research, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.; Cabré-Romans JJ; Program in Cancer Research, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.; González A; Pathology Department, Hospital del Mar, Barcelona, Spain.; Fernández L; Pathology Department, Hospital del Mar, Barcelona, Spain.; Marruecos L; Program in Cancer Research, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain; The Walter and Eliza Hall Institute, Melbourne, Australia.; Guix M; Oncology Department, Hospital del Mar, Barcelona, Spain.; Cuatrecasas M; Pathology Department, Centre of Biomedical Diagnosis (CDB), Hospital Clinic, 08036 Barcelona, Spain; Centro de Investigacion Biomedica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), 28029 Madrid, Spain; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.; López S; Pathology Department, Centre of Biomedical Diagnosis (CDB), Hospital Clinic, 08036 Barcelona, Spain; Centro de Investigacion Biomedica en Red en Enfermedades Hepáticas y Digestivas (CIBEREHD), 28029 Madrid, Spain.; Bellosillo B; Pathology Department, Hospital del Mar, Barcelona, Spain.; Torres F; Biostatistics Unit, Medical School, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.; Iglesias M; Pathology Department, Hospital del Mar, Barcelona, Spain; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain.; Bigas A; Program in Cancer Research, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain; Josep Carreras Leukemia Research Institute, Barcelona, Spain.; Espinosa L; Program in Cancer Research, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain; Centro de Investigacion Biomedica en Red Cancer (CIBERONC), Madrid, Spain. Electronic address: lespinosa@imim.es.
Source
Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101731731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-2596 (Electronic) Linking ISSN: 01674889 NLM ISO Abbreviation: Biochim Biophys Acta Mol Cell Res Subsets: MEDLINE
Subject
Language
English
Abstract
Background: We have previously shown that non-curative chemotherapy imposes fetal conversion and high metastatic capacity to cancer cells. From the set of genes differentially expressed in Chemotherapy Resistant Cells, we obtained a characteristic fetal intestinal cell signature that is present in a group of untreated tumors and is sufficient to predict patient prognosis. A feature of this fetal signature is the loss of CDX1.
Methods: We have analyzed transcriptomic data in public datasets and performed immunohistochemistry analysis of paraffin embedded tumor samples from two cohorts of colorectal cancer patients.
Results: We demonstrated that low levels of CDX1 are sufficient to identify patients with poorest outcome at the early tumor stages II and III. Presence tumor areas that are negative for CDX1 staining in stage I cancers is associated with tumor relapse.
Conclusions: Our results reveal the actual possibility of incorporating CDX1 immunostaining as a valuable biomarker for CRC patients.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
Methods: We have analyzed transcriptomic data in public datasets and performed immunohistochemistry analysis of paraffin embedded tumor samples from two cohorts of colorectal cancer patients.
Results: We demonstrated that low levels of CDX1 are sufficient to identify patients with poorest outcome at the early tumor stages II and III. Presence tumor areas that are negative for CDX1 staining in stage I cancers is associated with tumor relapse.
Conclusions: Our results reveal the actual possibility of incorporating CDX1 immunostaining as a valuable biomarker for CRC patients.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)